Strongbridge Biopharma plc is a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The Company’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for treatment options. The Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
